Bayer Aktiengesellschaft

Mithat Mardin

Wolf-Dieter Busse

Elisabeth Perzborn

Friedel Seuter

Volker Fiedler

Dieter Mayer

Friedrich Hoffmeister

Klaus Schlossmann

Rudiger Sitt

Hans P Krause

Edmund Krauthausen

Hans-Josef Buysch

Erich Klauke

Alexander Klausener

Horst Meyer

Harald Horstmann

Siegfried Raddatz

Hans-Joachim Kabbe

Gerd Fengler

Rudolf Sundermann

Rudi Grutzmann

Ekkehard Niemers

Bernhard Pelster

Hartmut Stegelmeier

Siegfried Linke

New potent lipoxygenase inhibitors which are 1H-pyrido-[2,3-b][1,4] thiazines are disclosed. The new thiazines are of the formula ##STR1## in which R.sup.1 denotes hydrogen, halogen, optionally substituted alkyl or alkoxy or the group ##STR2## in which R.sup.5 and R.sup.6 are identical or different and denote hydrogen, optionally substituted alkyl or aryl, or can be linked to form a 5- or 6-membered heterocyclic ring,

1H-pyrido-(2,3-b) (1,4)-thiazines

A method of inhibiting lipoxygenase in a patient, for the prophylaxis and/or treatment of ischaemias and disorders in cardiac rhythm, inflammations of the skin and the eye, and of rheumatic, allergic and asthmatic diseases, oedemas, pulmonary embolisms, pulmonary hypertension, shock lung, oxygen intoxications and ulcerations which comprises administering to such patient an effective amount of a compound of the formula ##STR1## wherein R represents an aryl or heteroaryl radical which has 6 to 12 C atoms and optionally contains 1 to 3 identical or different substituents from the group comprising halogen, trifluoromethyl, alkyl, alkenyl, alkoxy, alkylamino, cyano, trifluoromethoxy, nitro, hydroxyl, SO.sub.n -alkyl (n=0 to 2) or SO.sub.n -trifluoromethyl (n=0 to 2), alkyl, alkenyl and alkoxy in each case being understood as meaning radicals with 1 to 4 C atoms,

Inhibiting lipoxygenase with pyrazolone derivatives

Combating diseases of the respiratory tract, inflammations, rheumatism, thromboembolic diseases, ischaemias and infarcts, cardiac arrhythmias and arteriosclerosis with pyrazolediones of the formula ##STR1## wherein R represents an aryl or heteroaryl radical which has 6 to 12 C atoms and optionally contains 1 to 3 identical or different substituents from the group comprising halogen, trifluoromethyl, alkyl, alkenyl, alkoxy, alkylamino, cyano, trifluoromethoxy, nitro, hydroxyl, SO.sub.n -alkyl (n=0 to 2) or SO.sub.n -trifluoromethyl ) n=0 to 2), alkyl, alkenyl and alkoxy each having up to 4 C atoms,

Lipoxygenase inhibiting 1-arylalkyl-, 1-arylthio-, and

A method of inhibiting lipoxygenase in a patient, for the prophylaxis and/or treatment of ischaemias and disorders in cardiac rhythm and of rheumatic, allergic and asthmatic diseases, oedemas, pulmonary embolisms, pulmonary hypertension, oxygen intoxications and ulcerations which comprises administering to such patient an effective amount of nafazatrom.

Nafazatrom as a lipoxygenase inhibitor

The present invention refers to novel anellated 4H-1,4-benzothiazines, several processes for the synthesis thereof, their use as pharmaceutical agents, in particular their use as lipoxygenase-inhibiting agents, pharmaceutical compositions containing the novel benzothiazines and a process for their manufacture.

Anti-thrombotic pharmaceutical compositions comprising

The invention relates to pyrazolooxazines, pyrazolothiazines and pyrazoloquinolines defined herein by Formula I. The invention also includes compositions containing said Formula I compounds and methods for the use of said compounds and compositions for their lipoxygenase-inhibiting properties. Also included in the invention are methods for the manufacture of said compounds of Formula I.

Pyrazolooxazines, pyrazolothiazines, and pryazoloquinolines and their

The invention relates to cyclic sulphenamides of Formula I and methods for their manufacture. Also included in the invention are compositions containing said cyclic sulphenamides and methods for the use of said compounds and compositions as lipoxygenase inhibitors.

Cyclic sulphenamide compounds, their production and their medicinal use

The invention relates to sulphenamide compounds of Formula (I) as defined herein and to methods for their preparation. Also included in the invention are compositions containing said sulphenamide compounds; and the use of said compounds and compositions as lipoxygenase inhibiting agent.

Sulphenamides-containing lipoxygenase inhibiting agents and their use in

The invention relates primarily to pharmaceutical compositions and medicaments containing a compound of Formula (I), infra as the active ingredient. Also included in the invention are methods for combatting lipometabolic illnesses by administration of an active compound of the invention alone, in combination with a diluent or in the form of a medicament.

Medicaments for the treatment of disorders of lipometabolism and their

The invention relates to polyethers having an an average molecule weight of 3000 to 5000 and having a propylene oxide proportion of 60 to 80% and an ethylene oxide proportion of 20 to 40%. Also included in the invention are compositions containing said polyethers and methods for the use of said polyethers and compositions, particularly for their anti-lipidaemic effect.

Growing community of inventors

Wuppertal, Germany

Mithat Mardin